NO942300L - Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin - Google Patents

Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin

Info

Publication number
NO942300L
NO942300L NO942300A NO942300A NO942300L NO 942300 L NO942300 L NO 942300L NO 942300 A NO942300 A NO 942300A NO 942300 A NO942300 A NO 942300A NO 942300 L NO942300 L NO 942300L
Authority
NO
Norway
Prior art keywords
histidine
growth hormone
pharmaceutical preparation
stabilized pharmaceutical
derivative
Prior art date
Application number
NO942300A
Other languages
English (en)
Norwegian (no)
Other versions
NO942300D0 (no
Inventor
Hans Holmegaard Soerensen
Lars Skriver
Annie Rassing Hoelgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942300D0 publication Critical patent/NO942300D0/no
Publication of NO942300L publication Critical patent/NO942300L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO942300A 1991-12-20 1994-06-17 Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin NO942300L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (fr) 1991-12-20 1992-12-16 Formulation pharmaceutique stabilisee comportant une somatotrophine et de l'histidine

Publications (2)

Publication Number Publication Date
NO942300D0 NO942300D0 (no) 1994-06-17
NO942300L true NO942300L (no) 1994-08-19

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942300A NO942300L (no) 1991-12-20 1994-06-17 Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin

Country Status (24)

Country Link
EP (2) EP0618807B1 (fr)
JP (2) JP2950617B2 (fr)
KR (1) KR100266502B1 (fr)
AT (2) ATE368472T1 (fr)
AU (1) AU667503B2 (fr)
BG (1) BG63075B1 (fr)
CA (1) CA2125855C (fr)
CZ (1) CZ283361B6 (fr)
DE (3) DE69232847T2 (fr)
DK (1) DK0618807T3 (fr)
ES (2) ES2291264T3 (fr)
FI (1) FI115116B (fr)
HU (1) HUT69402A (fr)
IL (1) IL104152A (fr)
MX (1) MX9207374A (fr)
NL (1) NL300126I1 (fr)
NO (1) NO942300L (fr)
NZ (1) NZ246556A (fr)
PT (1) PT618807E (fr)
RO (1) RO111990B1 (fr)
RU (1) RU2122426C1 (fr)
SK (1) SK279641B6 (fr)
UA (1) UA41502C2 (fr)
WO (1) WO1993012812A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
JP3829991B2 (ja) * 1994-06-17 2006-10-04 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ ベノートスハップ Ｈｇｈ含有医薬組成物
TW426737B (en) * 1994-06-27 2001-03-21 Hayashibara Biochem Lab Saccharide composition with reduced reducibility, and preparation and uses thereof
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
AU4329596A (en) * 1995-01-13 1996-07-31 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
JP2001522793A (ja) * 1997-11-12 2001-11-20 アルザ コーポレイション 経皮電気輸送送達用の緩衝処理された薬物処方物
EP2311436A1 (fr) * 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Cristaux de protéines stabilisées, formulations renfermant lesdits cristaux et leurs procèdes de fabrication
MXPA02008261A (es) 2000-02-24 2002-11-29 Monsanto Technology Llc Formulaciones inyectables no acuosas para liberacion prolongada de somatotorpina.
KR20030023878A (ko) 2000-06-26 2003-03-20 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 계면활성제 함유비수성 제제들
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
BR0209154A (pt) 2001-05-18 2004-07-20 Danisco Processo de preparação de uma massa com uma enzima
NZ571243A (en) * 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
KR20050090430A (ko) 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
WO2005012347A2 (fr) 2003-08-05 2005-02-10 Novo Nordisk A/S Nouveaux derives de l'insuline
EP1776455B1 (fr) 2004-07-16 2015-03-18 DuPont Nutrition Biosciences ApS Enzymes lipotiques, utilisations de ceux-ci dans l'industrie alimentaire
PL1827483T3 (pl) * 2004-12-15 2014-12-31 Swedish Orphan Biovitrum Ab Publ Formulacje terapeutyczne czynnika wzrostu keratynocytów
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
JP2009506096A (ja) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー ペグ化成長ホルモンの液状調製物
WO2007033427A1 (fr) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation de peptides comprenant des acides aminés basiques
EP2505593A1 (fr) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions renfermant de l'insuline acylée et du zinc et procédé de fabrication des dites compositions
MX2008016169A (es) 2006-07-07 2009-01-15 Novo Nordisk Healthcare Ag Nuevos conjugados de proteina y metodos para su preparacion.
EP2486916B1 (fr) * 2006-12-18 2015-04-01 Ajinomoto Althea, Inc. Formules d'hormone à croissance humaine
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
BRPI0923047B8 (pt) * 2008-12-16 2021-05-25 Genzyme Corp métodos para preparação de conjugados de proteínas- oligossacarídeos
WO2010096394A2 (fr) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
AU2010341516B2 (en) 2009-12-21 2014-01-16 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
NZ607633A (en) * 2010-09-21 2014-07-25 Ferring Bv Improved process for production of recombinant human growth hormone
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
BR112013017980A2 (pt) 2011-01-14 2017-06-27 Redwood Bioscience Inc polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
CN104349768B (zh) 2012-06-05 2017-11-07 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6134081B1 (ja) * 2015-12-10 2017-05-24 株式会社メニコン ペプチド組成物
WO2017189432A1 (fr) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Conjugués d'anticorps et méthodes de fabrication et d'utilisation de ceux-ci
SG11202011353XA (en) * 2018-05-25 2020-12-30 Dr Reddys Laboratories Ltd Stable fusion protein formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
SG11202103137WA (en) 2018-10-26 2021-04-29 Novo Nordisk As Stable semaglutide compositions and uses thereof
WO2022197963A1 (fr) * 2021-03-19 2022-09-22 Pfizer Inc. Compositions d'hormone de croissance à action prolongée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0374120A3 (fr) * 1988-12-13 1991-07-31 Monsanto Company Composition pour la libération contrôlée des polypeptides
DK168790D0 (fr) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
FI942906A (fi) 1994-06-17
DE69232847T2 (de) 2003-09-11
RO111990B1 (ro) 1997-04-30
KR100266502B1 (ko) 2000-09-15
IL104152A (en) 1998-06-15
EP0618807A1 (fr) 1994-10-12
IL104152A0 (en) 1993-05-13
WO1993012812A1 (fr) 1993-07-08
EP1197222B1 (fr) 2007-08-01
EP0618807B1 (fr) 2002-11-13
CA2125855A1 (fr) 1993-07-08
DE69233704T2 (de) 2008-05-21
UA41502C2 (uk) 2001-09-17
ATE227583T1 (de) 2002-11-15
BG63075B1 (bg) 2001-03-30
RU2122426C1 (ru) 1998-11-27
CZ150794A3 (en) 1995-01-18
NO942300D0 (no) 1994-06-17
DE10399015I1 (de) 2012-05-03
AU667503B2 (en) 1996-03-28
DE10399015I2 (de) 2008-08-07
SK279641B6 (sk) 1999-01-11
NL300126I1 (nl) 2003-07-01
JPH07502516A (ja) 1995-03-16
JP2950617B2 (ja) 1999-09-20
MX9207374A (es) 1993-07-01
JPH11315031A (ja) 1999-11-16
CZ283361B6 (cs) 1998-03-18
RU94045932A (ru) 1997-04-20
SK75494A3 (en) 1995-03-08
AU3344693A (en) 1993-07-28
DK0618807T3 (da) 2003-03-03
NZ246556A (en) 1996-03-26
FI115116B (fi) 2005-03-15
HU9401832D0 (en) 1994-09-28
FI942906A0 (fi) 1994-06-17
EP1197222A2 (fr) 2002-04-17
HUT69402A (en) 1995-09-28
DE69233704D1 (de) 2007-09-13
ES2185625T3 (es) 2003-05-01
EP1197222A3 (fr) 2004-02-04
BG98806A (bg) 1995-02-28
DE69232847D1 (de) 2002-12-19
PT618807E (pt) 2003-03-31
CA2125855C (fr) 2008-05-13
ES2291264T3 (es) 2008-03-01
ATE368472T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
NO942300D0 (no) Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin
NO942299D0 (no) Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin
ES2173197T3 (es) Una formula farmaceutica que contiene hormona de crecimiento e isoleucina.
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
NO980103L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon og et peptid omfattende minst én basisk aminosyrerest og minst én sur aminosyrerest
GB2021581A (en) Stabilisation of PGl2 derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application